[3]魏常博.纳米材料和纳米技术在肿瘤放疗增敏中的研究进展[J].口腔疾病防治,2017,25(11):744-748.

[4]PRABHAKAR U, MAEDA H, JAIN K, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 2013;73(8):2412-2417.

[5]刘艳红,周建平,霍美蓉.肿瘤微环境响应型智能纳米药物载体的研究进展[J].中国药科大学学报,2016,47(2):4-12.

[6]贺瑞,甘杨子,钟克焱,等.纳米抗肿瘤药物及其研究进展[J].现代养生(下半月版),2019(2):109-110.

[7]AMREDDY N, BABU A, MURALIDHARAN R, et al. Recent Advances in Nanoparticle-Based Cancer Drug and Gene Delivery. Adv Cancer Res. 2018;137:115-170.

[8]BEHZADI S, SERPOOSHAN V, TAO W, et al. Cellular uptake of nanoparticles:journey inside the cell. Chem Soc Rev. 2017;46(14):4218-4244.

[9]CHEN B, DAI W, HE B, et al. Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment. Theranostics, 2017;7(3):538-558.

[10]ZHANG H, LIU XL, ZHANG YF, et al. Magnetic nanoparticles based cancer therapy: current status and applications. Sci China Life Sci. 2018;61(4):400-414.

[11]刘耀阳,王荣梅.酶响应纳米粒子共输送地西他滨阿霉素逆转乳腺癌多药耐药[J].药物生物技术,2018,25(4):288-293.

[12]KUMAR B, KULANTHAIVEL S, MONDAL A, et al. Mesoporous silica nanoparticle based enzyme responsive system for colon specific drug delivery through guar gum capping. Colloids Surf B Biointerfaces. 2017;150:352-361.

[13]刘新,马铭怿.基质金属蛋白酶响应的紫杉醇-二氢卟吩e6纳米粒子诱导结肠癌细胞凋亡[J].药物生物技术,2019,26(3):211-216.

[14]JIANG H, SHI X, YU X, et al. Hyaluronidase Enzyme-responsive Targeted Nanoparticles for Effective Delivery of 5-Fluorouracil in Colon Cancer. Pharm Res. 2018;35(4):73.

[15]李辉盛,苏子桓,王冠海.酶刺激响应纳米载体的制备与负载姜黄素体外释放研究[J].山东化工,2018,47(20):18-19.

[16]ZHANG C, PAN D, LUO K, et al. Peptide Dendrimer-doxorubicin Conjugate-Based Nanoparticles as an Enzyme-Responsive Drug Delivery System for Cancer Therapy. Adv Healthc Mater. 2014;3(8):1299-1308.

[17]BEN-NUN Y, FICHMAN G, ADLER-ABRAMOVICH L, et al. Cathepsin nanofiber substrates as potential agents for targeted drug delivery. J Control ;257:60-67.

[18]DE LA TORRE C, MONDRAGóN L, COLL C, et al. Cathepsin-B induced controlled release from peptide-capped mesoporous silica 2014;20(47):-.

[19]VAN RIJT SH, B?LüKBAS DA, ARGYO C, et al. Protease-Mediated Release of Chemotherapeutics from Mesoporous Silica Nanoparticles to ex Vivo Human and Mouse Lung Tumors. ACS Nano. 2015;9(3):2377-2389.

[20]SHI L, HU Y, LIN A, et al. Matrix Metalloproteinase Responsive Nanoparticles for Synergistic Treatment of Colorectal Cancer via Simultaneous Anti-Angiogenesis and Chemotherapy. Bioconjug Chem. 2016;27(12):2943-2953.

[21]ZHOU Y, ZHANG S, CHEN Z, et al. Targeted Delivery of Secretory Promelittin via Novel Poly(lactone-co-β-amino ester) Nanoparticles for Treatment of Breast Cancer Brain Metastases. Adv Sci (Weinh). 2020;7(5):.

[22]JALLOUK AP, PALEKAR RU, MARSH JN, et al. Delivery of a Protease-Activated Cytolytic Peptide Prodrug by Perfluorocarbon Nanoparticles. Bioconjug Chem. 2015;26(8):1640-1650.

[23]YE M, HAN Y, TANG J, et al. A Tumor-Specific Cascade Amplification Drug Release Nanoparticle for Overcoming Multidrug Resistance in Cancers. Adv Mater. 2017;29(38):.

[24]LIU Y, DING X, LI J, et al. Enzyme responsive drug delivery system based on mesoporous silica nanoparticles for tumor therapyin vivo. ;26(14):.

[25]CHENG YJ, LUO GF, ZHU JY, et al. Enzyme-induced and tumor-targeted drug delivery system based on multifunctional mesoporous silica Appl Mater Interfaces. 2015;7(17):9078-9087.

[26]BERNARDOS A, MONDRAGON L, AZNAR E, et al. Enzyme-responsive intracellular controlled release using nanometric silica mesoporous supports capped with “saccharides”. ACS Nano. 2010;4(11):6353-6368.

[27]LEE J, OH ET, YOON H, et al. Mesoporous nanocarriers with a stimulusresponsive cyclodextrin gatekeeper for targeting tumor hypoxia. ;9(20):6901-6909.

[28]NAZ S, WANG M, HAN Y, et al. Enzyme-responsive mesoporous silica nanoparticles for tumor cells and mitochondria multistage-targeted drug delivery. Int J Nanomedicine. 2019;14:2533-2542.

[29]ZHANG M, XU C, WEN L, et al. A Hyaluronidase-Responsive Nanoparticle-Based Drug Delivery System for Targeting Colon Cancer Cells. Cancer Res.2016;76(24):7208-7218.

[30]CHEN Z, LI Z, LIN Y, et al. Bioresponsive hyaluronic acid-capped mesoporous silica nanoparticles for targeted drug delivery. Chemistry. 2013;19(5):1778-1783.

[31]LEE SJ, JEONG YI, PARK HK, et al. Enzyme-responsive doxorubicin release from dendrimer nanoparticles for anticancer drug delivery. Int J Nanomedicine. 2015;10:5489-5503.

[32]RENOUX B, RAES F, LEGIGAN T, et al. Targeting the tumour microenvironment with an enzyme-responsive drug delivery system for the efficient therapy of breast and pancreatic cancers. Chem Sci. 2017;8(5):3427-3433.

文章来源：《肿瘤药学》 网址: http://www.zlyxzz.cn/qikandaodu/2021/0222/665.html